secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001628280-24-047276
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Q3 total rev $89M (+61% YoY) includes $45M deferred release; core $44M (-21%); guides FY $215-235M
--------------------------------------------------------------------------------

- Total revenue $89M (+61% YoY) incl. $45M non-cash deferred revenue; core rev $44M (-21%).
- Cell Engineering ex-deferred $30M (-20% YoY); Biosecurity $14M with 28% gross margin.
- Loss from ops $(55)M vs $(286)M; Adj EBITDA $(20)M vs $(84)M.
- FY24 guidance raised: Total rev $215-235M, Cell Eng $165-185M, Biosecurity ≥$50M.
- Appointed Dr. Sri Kosuri to Board; Dr. Belldegrun resigned. Signed deal with Novo Nordisk; Merck milestone $9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000162828024047276/0001628280-24-047276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000162828024047276/dna-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-047276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer